Puma Biotechnology (PBYI) Gross Profit (2017 - 2026)

Puma Biotechnology has reported Gross Profit for 10 years, with the latest figure at $34.4 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit fell 2.99% year-over-year to $34.4 million; the trailing twelve-month figure through Mar 2026 stood at $169.2 million (changed 0.4% YoY), and the FY2025 full-year result was $170.2 million, up 2.5% from the prior year.
• Gross Profit for Q1 2026 stood at $34.4 million, down from $52.3 million in the prior quarter.
• The five-year high for Gross Profit was $70.8 million in Q4 2022, with the low at $33.0 million in Q1 2024.
• Historically, Gross Profit has averaged $43.4 million across 5 years, with a median of $42.7 million in 2023.
• The largest YoY upside for Gross Profit was 62.92% in 2022 against a maximum downside of 49.15% in 2022.
• Puma Biotechnology's Gross Profit stood at $70.8 million in 2022, then plunged by 32.42% to $47.9 million in 2023, then slipped by 5.64% to $45.2 million in 2024, then rose by 15.88% to $52.3 million in 2025, then slumped by 34.28% to $34.4 million in 2026.
• The last three Gross Profit figures came in at $34.4 million (Q1 2026), $52.3 million (Q4 2025), and $42.3 million (Q3 2025), per Business Quant data.